- Home
- CAVA vs MRNA Comparison
CAVA vs MRNA Comparison
Compare CAVA & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAVA
- MRNA
- Stock Information
- Founded
- CAVA 2006
- MRNA 2010
- Country
- CAVA United States
- MRNA United States
- Employees
- CAVA N/A
- MRNA N/A
- Industry
- CAVA Restaurants
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CAVA Consumer Discretionary
- MRNA Health Care
- Exchange
- CAVA Nasdaq
- MRNA Nasdaq
- Market Cap
- CAVA 9.7B
- MRNA 11.1B
- IPO Year
- CAVA 2023
- MRNA 2018
- Fundamental
- Price
- CAVA $91.42
- MRNA $33.30
- Analyst Decision
- CAVA Buy
- MRNA Hold
- Analyst Count
- CAVA 15
- MRNA 19
- Target Price
- CAVA $115.87
- MRNA $48.13
- AVG Volume (30 Days)
- CAVA 4.5M
- MRNA 9.9M
- Earning Date
- CAVA 08-21-2025
- MRNA 07-31-2025
- Dividend Yield
- CAVA N/A
- MRNA N/A
- EPS Growth
- CAVA 274.67
- MRNA N/A
- EPS
- CAVA 1.20
- MRNA N/A
- Revenue
- CAVA $1,036,533,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- CAVA $26.28
- MRNA N/A
- Revenue Next Year
- CAVA $21.53
- MRNA $9.70
- P/E Ratio
- CAVA $76.74
- MRNA N/A
- Revenue Growth
- CAVA 32.11
- MRNA N/A
- 52 Week Low
- CAVA $70.00
- MRNA $23.15
- 52 Week High
- CAVA $172.43
- MRNA $129.39
- Technical
- Relative Strength Index (RSI)
- CAVA 67.16
- MRNA 70.05
- Support Level
- CAVA $72.36
- MRNA $29.72
- Resistance Level
- CAVA $92.47
- MRNA $34.39
- Average True Range (ATR)
- CAVA 3.74
- MRNA 1.48
- MACD
- CAVA 1.87
- MRNA 0.68
- Stochastic Oscillator
- CAVA 93.50
- MRNA 88.62
About CAVA CAVA Group Inc.
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.